Detalhe da pesquisa
1.
Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab.
Cell
; 171(4): 934-949.e16, 2017 Nov 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-29033130
2.
Nivolumab plus ipilimumab in advanced melanoma.
N Engl J Med
; 369(2): 122-33, 2013 Jul 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-23724867
3.
Metastasis gets site specific.
Cancer Cell
; 8(2): 93-5, 2005 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-16098461
4.
Hallmarks of Resistance to Immune-Checkpoint Inhibitors.
Cancer Immunol Res
; 10(4): 372-383, 2022 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35362046
5.
Altered gene and protein expression by Nm23-H1 in metastasis suppression.
Mol Cell Biochem
; 329(1-2): 141-8, 2009 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-19415462
6.
Clinical-translational approaches to the Nm23-H1 metastasis suppressor.
Clin Cancer Res
; 14(16): 5006-12, 2008 Aug 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-18698018
7.
Nm23-H1 suppresses tumor cell motility by down-regulating the lysophosphatidic acid receptor EDG2.
Cancer Res
; 67(15): 7238-46, 2007 Aug 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-17671192
8.
irRECIST for the Evaluation of Candidate Biomarkers of Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma: Analysis of a Phase II Prospective Clinical Trial.
Clin Cancer Res
; 25(7): 2174-2184, 2019 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30670497
9.
Nm23-H1 homologs suppress tumor cell motility and anchorage independent growth.
Clin Exp Metastasis
; 25(2): 131-8, 2008.
Artigo
em Inglês
| MEDLINE | ID: mdl-18058029
10.
The role of metastasis suppressor genes in metastatic dormancy.
APMIS
; 116(7-8): 586-601, 2008.
Artigo
em Inglês
| MEDLINE | ID: mdl-18834404
11.
ExpressYourself: A modular platform for processing and visualizing microarray data.
Nucleic Acids Res
; 31(13): 3477-82, 2003 Jul 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-12824348
12.
Cancer Treatment with Anti-PD-1/PD-L1 Agents: Is PD-L1 Expression a Biomarker for Patient Selection?
Drugs
; 76(9): 925-45, 2016 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-27229745
13.
Safety, correlative markers, and clinical results of adjuvant nivolumab in combination with vaccine in resected high-risk metastatic melanoma.
Clin Cancer Res
; 21(4): 712-20, 2015 Feb 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-25524312
14.
Biomarker analysis of neoadjuvant doxorubicin/cyclophosphamide followed by ixabepilone or Paclitaxel in early-stage breast cancer.
Clin Cancer Res
; 19(6): 1587-95, 2013 Mar 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-23340299
15.
Validation of companion diagnostic for detection of mutations in codons 12 and 13 of the KRAS gene in patients with metastatic colorectal cancer: analysis of the NCIC CTG CO.17 trial.
Arch Pathol Lab Med
; 137(6): 820-7, 2013 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-23030695
16.
Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma.
J Clin Oncol
; 31(34): 4311-8, 2013 Dec 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-24145345
17.
Effect of inhibition of the lysophosphatidic acid receptor 1 on metastasis and metastatic dormancy in breast cancer.
J Natl Cancer Inst
; 104(17): 1306-19, 2012 Sep 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-22911670
18.
The cetuximab experience: developing predictive biomarkers in oncology.
Per Med
; 8(2): 149-159, 2011 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-29783412
19.
Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer.
J Clin Oncol
; 28(6): 918-27, 2010 Feb 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-20100958
20.
ChIP-chip: a genomic approach for identifying transcription factor binding sites.
Methods Enzymol
; 350: 469-83, 2002.
Artigo
em Inglês
| MEDLINE | ID: mdl-12073330